Yanxia Shi

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Venues

NPJ breast cancer

Cancer

The oncologist

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The oncologist 29 (8) (2024)
Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The oncologist 29 (8) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Mei-Ting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jincai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study. Cancer 130 (S8) (2024)
Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The oncologist (2024)
Mei-Ting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jincai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study. Cancer 130 (S8) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Mei-Ting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jincai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study. Cancer 130 (S8) (2024)
Mei-Ting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jincai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study. Cancer (2024)
Cong Xue, Haifeng Li, Herui Yao, Ying Lin, Xin An, Meiting Chen, Riqing Huang, Lu Li, Anqi Hu, Mengqian Ni, Lulu Zhang, Wei Yang, Zhonghui Xu, Su Li, Yanxia Shi
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. NPJ breast cancer 8 (1) (2022)
Cong Xue, Haifeng Li, Herui Yao, Ying Lin, Xin An, Meiting Chen, Riqing Huang, Lu Li, Anqi Hu, Mengqian Ni, Lulu Zhang, Wei Yang, Zhonghui Xu, Su Li, Yanxia Shi
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. NPJ breast cancer 8 (1) (2022)
Cong Xue, Haifeng Li, Herui Yao, Ying Lin, Xin An, Meiting Chen, Riqing Huang, Lu Li, Anqi Hu, Mengqian Ni, Lulu Zhang, Wei Yang, Zhonghui Xu, Su Li, Yanxia Shi
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. NPJ breast cancer 8 (1) (2022)
Xin An, Xuefen Lei, Riqing Huang, Rongzhen Luo, Haifeng Li, Fei Xu, Zhongyu Yuan, Shu-Sen Wang, Alexandre de Nonneville, Anthony Gonçalves, Gilles Houvenaeghel, JiBin Li, Cong Xue, Yanxia Shi
Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer (2021)
Ruoxi Hong, Wen Xia, Liye Wang, Kaping Lee, Qianyi Lu, Kuikui Jiang, Shengfeng Li, Jinquan Yu, Jin Wei, Weijia Tang, Danyang Zhou, Xin An, Jiajia Huang, Cong Xue, Xiwen Bi, Yanxia Shi, Zhongyu Yuan, Fei Xu, Shu-Sen Wang
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer communications (London, England) 41 (2) (2021)
Haifeng Li, Lu Li, Cong Xue, Riqing Huang, Anqi Hu, Xin An, Yanxia Shi
A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients. Biology 10 (2) (2021)
Ping-Chieh Chou, Hyun Ho Choi, Yizhi Huang, Enrique Fuentes-Mattei, Guermarie Velazquez-Torres, Fanmao Zhang, Liem Phan, Jaehyuk Lee, Yanxia Shi, James A Bankson, Yun Wu, Huamin Wang, Ruiying Zhao, Sai-Ching Jim Yeung, Mong-Hong Lee
Impact of diabetes on promoting the growth of breast cancer. Cancer communications (London, England) 41 (5) (2021)
Cong Xue, Wenwen Wei, Peng Sun, Wei Zheng, Xiaoju Diao, Fei Xu, Jiajia Huang, Xin An, Wen Xia, Ruoxi Hong, Kuikui Jiang, Riqing Huang, Zhongyu Yuan, Shusen Wang, Anhua Li, Ruhai Zou, Yanxia Shi
Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast cancer research and treatment 173 (3) (2018)

Yanxia Shi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yanxia Shi